A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

November 18, 2025 updated by: Bristol-Myers Squibb

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
190

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Expanded Access

Expanded Access

A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA). Also called compassionate use. There are different expanded access types.
Available

Available

  • Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
  • No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
  • Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
  • Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
 outside the clinical trial. See expanded access record.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: First line of the email MUST contain the NCT# and Site #.

Study Contact Backup

  • Name: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
  • Phone Number: 855-907-3286
  • Email: Clinical.Trials@bms.com

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1417DTB
        • Local Institution - 0207
      • Buenos Aires, Argentina, 1431
        • Local Institution - 0106
      • Córdoba, Argentina, 5000
        • Local Institution - 0093
    • Buenos Aires
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 1280
        • Local Institution - 0092
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1426ANZ
        • Instituto Alexander Fleming
    • Buenos Aires F.D.
      • ABB, Buenos Aires F.D., Argentina, C1199ABB
        • Local Institution - 0091
  • Austria
      • Vienna, Austria, 1210
        • Local Institution - 0041
  • Brazil
      • Rio de Janeiro, Brazil, 22061-080
        • Local Institution - 0098
      • Rio de Janeiro, Brazil, 22250-905
        • Local Institution - 0108
      • São Paulo, Brazil, 01401-002
        • Local Institution - 0032
      • São Paulo, Brazil, 05652-900
        • Local Institution - 0114
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30380-490
        • Local Institution - 0073
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazil, 90110-270
        • Local Institution - 0033
      • Porto Alegre, Rio Grande do Sul, Brazil, 90610-000
        • Local Institution - 0034
    • São Paulo
      • Barretos, São Paulo, Brazil, 14784400
        • Local Institution - 0029
      • São José do Rio Preto, São Paulo, Brazil, 15090000
        • Local Institution - 0037
      • São Paulo, São Paulo, Brazil, 01308-060
        • Local Institution - 0209
      • São Paulo, São Paulo, Brazil, 01321-001
        • Local Institution - 0147
  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Local Institution - 0002
    • Quebec
      • Trois-Rivières, Quebec, Canada, G8Z 3R9
        • Local Institution - 0123
  • Chile
    • Región de Valparaíso
      • Viña del Mar, Región de Valparaíso, Chile, 2520598
        • Local Institution - 0096
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7500921
        • Fundacion Arturo Lopez Perez (FALP)
  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100142
        • Local Institution - 0168
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400042
        • Local Institution - 0185
    • Fujian
      • Xiamen, Fujian, China, 361003
        • Local Institution - 0169
    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Local Institution - 0180
    • Guangxi
      • Nanning, Guangxi, China, 530000
        • Local Institution - 0194
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150000
        • Local Institution - 0171
    • Henan
      • Zhengzhou, Henan, China, 450003
        • Local Institution - 0166
    • Hubei
      • Wuhan, Hubei, China, 430079
        • Local Institution - 0181
    • Hunan
      • Changsha, Hunan, China, 410000
        • Local Institution - 0184
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Local Institution - 0193
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Local Institution - 0202
    • Jilin
      • Changchun, Jilin, China, 130012
        • Local Institution - 0178
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Local Institution - 0183
    • Shandong
      • Jinan, Shandong, China, 250000
        • Local Institution - 0186
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200030
        • Local Institution - 0164
      • Shanghai, Shanghai Municipality, China, 200032
        • Local Institution - 0179
    • Sichuan
      • Chengdu, Sichuan, China, 610044
        • Local Institution - 0177
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
        • Local Institution - 0175
  • France
      • Paris, France, 75014
        • Local Institution - 0056
    • Alsace
      • Strasbourg, Alsace, France, 67091
        • Local Institution - 0059
    • Aquitaine
      • Pessac, Aquitaine, France, 33600
        • Local Institution - 0055
    • Côte-d'Or
      • Dijon, Côte-d'Or, France, 21079
        • Local Institution - 0109
    • Haute-Normandie
      • Rouen, Haute-Normandie, France, 76031
        • Local Institution - 0057
    • Isère
      • La Tronche, Isère, France, 38700
        • Local Institution - 0058
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, France, 44800
        • Local Institution - 0189
    • Rhône
      • Pierre-Bénite, Rhône, France, 69310
        • Local Institution - 0060
  • Germany
      • Berlin, Germany, 13125
        • Evangelische Lungenklinik Berlin
      • Cologne, Germany, 50937
        • Universitaetsklinikum Koeln
      • Dresden, Germany, 01307
        • Local Institution - 0035
      • Gauting, Germany, 82131
        • Asklepios Klinik Gauting GmbH
      • Immenhausen, Germany, 34376
        • Lungenfachklinik Immenhausen
      • Mainz, Germany, 55131
        • Marienhaus Klinikum Mainz
    • Baden-Wurttemberg
      • Esslingen am Neckar, Baden-Wurttemberg, Germany, 73730
        • Klinikum Esslingen
    • Bavaria
      • Würzburg, Bavaria, Germany, 97074
        • Klinikum Würzburg Mitte
    • Lower Saxony
      • Oldenburg, Lower Saxony, Germany, 26121
        • Local Institution - 0074
  • Greece
    • Achaḯa
      • Pátrai, Achaḯa, Greece, 26504
        • Local Institution - 0154
    • Attikí
      • Athens, Attikí, Greece, 115 27
        • Local Institution - 0153
      • Chaïdári, Attikí, Greece, 124 62
        • Local Institution - 0155
    • Kentrikí Makedonía
      • Thessaloniki, Kentrikí Makedonía, Greece, 540 07
        • "Theagenio" Cancer Hospital of Thessaloniki
  • Hungary
      • Budapest, Hungary, 1121
        • Local Institution - 0135
  • India
    • Gujarat
      • Ahmedabad, Gujarat, India, 380054
        • Local Institution - 0102
      • Ahmedabad, Gujarat, India, 380060
        • Local Institution - 0118
    • Haryana
      • Gurugram, Haryana, India, 122001
        • Local Institution - 0044
    • Karnataka
      • Bengaluru, Karnataka, India, 560017
        • Local Institution - 0082
    • Maharashtra
      • Pune, Maharashtra, India, 411001
        • Local Institution - 0045
      • Pune, Maharashtra, India, 411004
        • Local Institution - 0049
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110029
        • Local Institution - 0218
      • New Delhi, National Capital Territory of Delhi, India, 110085
        • Local Institution - 0076
  • Italy
    • Friuli Venezia Giulia
      • Aviano, Friuli Venezia Giulia, Italy, 33081
        • Local Institution - 0151
    • Lombardy
      • Milan, Lombardy, Italy, 20133
        • Local Institution - 0152
      • Monza, Lombardy, Italy, 20900
        • Local Institution - 0149
    • Napoli
      • Naples, Napoli, Italy, 80131
        • Local Institution - 0150
    • Roma
      • Rome, Roma, Italy, 00144
        • Local Institution - 0148
  • Japan
      • Fukuoka, Japan, 811-1395
        • Local Institution - 0195
      • Osaka, Japan, 534-0021
        • Local Institution - 0160
      • Osaka, Japan, 541-8567
        • Local Institution - 0167
      • Tokyo, Japan, 164-8541
        • Tokyo Metropolitan Police Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 466-8560
        • Local Institution - 0190
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • Local Institution - 0132
    • Ehime
      • Matsuyama, Ehime, Japan, 791-0280
        • Local Institution - 0174
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 060-8648
        • Local Institution - 0163
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 2418515
        • Local Institution - 0173
    • Miyagi
      • Sendai, Miyagi, Japan, 9800873
        • Sendai Kosei Hospital
    • Tokyo
      • Bunkyo Ku, Tokyo, Japan, 113-8677
        • Tokyo Metropolitan Komagome Hospital
    • Tottori
      • Yonago, Tottori, Japan, 683-8504
        • Local Institution - 0159
  • Netherlands
    • North Holland
      • Amsterdam, North Holland, Netherlands, 1081 HV
        • Local Institution - 0216
  • Poland
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Poland, 20-609
        • Local Institution - 0187
    • Warmian-Masurian Voivodeship
      • Olsztyn, Warmian-Masurian Voivodeship, Poland, 10-357
        • Local Institution - 0196
  • Romania
      • Cluj-Napoca, Romania, 400015
        • Local Institution - 0122
      • Iași, Romania, 700106
        • Local Institution - 0067
    • București
      • Bucharest, București, Romania, 022328
        • Local Institution - 0066
      • Bucharest, București, Romania, 013812
        • Local Institution - 0030
    • Dolj
      • Craiova, Dolj, Romania, 200746
        • Local Institution - 0031
  • South Korea
    • Chungcheongbuk-do [Chungbuk]
      • Cheongju-si, Chungcheongbuk-do [Chungbuk], South Korea, 28644
        • Local Institution - 0062
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, South Korea, 13620
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [Seoul]
      • Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 05505
        • Asan Medical Center
      • Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 06351
        • Local Institution - 0063
  • Spain
      • Málaga, Spain, 29011
        • Local Institution - 0142
      • Seville, Spain, 41013
        • Local Institution - 0144
      • Valencia, Spain, 46026
        • Local Institution - 0143
    • A Coruña [La Coruña]
      • A Coruña, A Coruña [La Coruña], Spain, 15006
        • Local Institution - 0141
      • Santiago de Compostela, A Coruña [La Coruña], Spain, 15706
        • Local Institution - 0138
    • Barcelona [Barcelona]
      • Barcelona, Barcelona [Barcelona], Spain, 08035
        • Local Institution - 0140
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spain, 28041
        • Local Institution - 0137
      • Majadahonda, Madrid, Comunidad de, Spain, 28222
        • Local Institution - 0139
  • Switzerland
    • Canton of Aargau
      • Baden, Canton of Aargau, Switzerland, 5404
        • Kantonspital Baden
  • Turkey (Türkiye)
      • Adana, Turkey (Türkiye), 01140
        • Local Institution - 0088
      • Ankara, Turkey (Türkiye), 06010
        • Local Institution - 0084
      • Istanbul, Turkey (Türkiye), 34214
        • Local Institution - 0087
      • Istanbul, Turkey (Türkiye), 34440
        • T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi
      • Istanbul, Turkey (Türkiye), 34899
        • Local Institution - 0083
      • Sakarya, Turkey (Türkiye)
        • Local Institution - 0085
    • Ankara
      • Yenimahalle, Ankara, Turkey (Türkiye), 06200
        • Local Institution - 0086
  • United States
    • Iowa
      • Des Moines, Iowa, United States, 50309
        • Local Institution - 0221
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Local Institution - 0075
      • Boston, Massachusetts, United States, 02215
        • Local Institution - 0201
    • New York
      • Mineola, New York, United States, 11501
        • Local Institution - 0210
      • New York, New York, United States, 10016
        • Local Institution - 0134
    • Washington
      • Tacoma, Washington, United States, 98405
        • Local Institution - 0214

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participant has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC
  • Participant has a ROS1 gene rearrangement/fusion as detected by a local test.
  • At least 1 measurable lesion according to RECIST v1.1, as assessed by the investigator.
  • Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC
  • Up to 1 prior line of systemic treatment for NSCLC is permitted
  • ECOG Performance Status ≤ 2

Exclusion Criteria:

  • Symptomatic brain metastases or symptomatic leptomeningeal involvement.
  • History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected.
  • Known tumor targetable co-mutations or rearrangements
  • Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment)

Note: Other protocol-defined inclusion/exclusion criteria apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Arm A
Drug: Repotrectinib
Specified dose on specified days
Other Names:
  • BMS-986472
Active Comparator: Arm B
Drug: Crizotinib
Specified dose on specified days
Other Names:
  • Xalkori

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Number of participants with Adverse Events (AEs), Serious AEs (SAEs), AEs leading to study intervention discontinuation, and drug-related AEs
Time Frame: Up to 30 days after last dose
Up to 30 days after last dose
Number of deaths
Time Frame: Up to 30 days after last dose
Up to 30 days after last dose
Number of participants without at least a 3-point change in the Non-Small Cell Lung Cancer-Symptom Assessment Questionnaire (NSCLC-SAQ) total score
Time Frame: Up to 30 days after last dose
Up to 30 days after last dose
Overall Survival (OS)
Time Frame: Up to approximately 41 months
Up to approximately 41 months
Overall Response Rate (ORR) as per BICR according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
ORR as per Investigator according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
Duration of Response (DOR) as per BICR according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
DOR as per Investigator according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
Time to Response (TTR) as per BICR according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
TTR as per Investigator according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
PFS as per Investigator according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months
Time to intracranial progressions as per BICR according to RECIST v1.1
Time Frame: Up to approximately 41 months
Up to approximately 41 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Zai Lab (Shanghai) Co., Ltd.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 21, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 13, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 15, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 15, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 15, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 20, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 21, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 18, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA127-1030
  • U1111-1292-0487 (Registry Identifier: WHO)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings